Login / Signup

Seroprevalence of severe acute respiratory syndrome coronavirus 2 N antibodies between December 2021 and march 2023 in Japan.

Seiya YamayoshiEtsuko NagaiKeiko MitamuraMasao HagiharaRyo KobayashiSatoshi TakahashiAkimichi ShibataYoshifumi UwaminoNaoki HasegawaAsef IqbalIsamu KamimakiKiyoko Iwatsuki-HorimotoTokiko Nagamura-InoueYoshihiro Kawaoka
Published in: Epidemiology and infection (2024)
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in 2019 in China and rapidly spread worldwide, leading to a pandemic. The threat of SARS-CoV-2 is subsiding as most people have acquired sufficient antibodies through vaccination and/or infection to prevent severe COVID-19. After the emergence of the omicron variants, the seroprevalence of antibodies against the N protein elicited by SARS-CoV-2 infection ranged from 44.4% to 80.2% in countries other than Japan. Here, we assessed the seroprevalence in Japan before and after the appearance of omicron variants. Serosurveillance of antibodies against N was conducted between December 2021 and March 2023 in Japan. In total, 7604 and 3354 residual serum or plasma samples were collected in the Tokyo metropolitan area and Sapporo, respectively. We found that the seroprevalence in representative regions of Japan increased approximately 3% to 23% after the emergence of the omicron variants. We also found higher seroprevalence among the young compared with the elderly. Our findings indicate that unlike other countries, most of the Japanese population has not been infected, raising the possibility of future SARS-CoV-2 epidemics in Japan.
Keyphrases
  • sars cov
  • respiratory syndrome coronavirus
  • coronavirus disease
  • copy number
  • middle aged
  • community dwelling